• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

头孢曲松单独或与替考拉宁联合用于门诊治疗癌症中性粒细胞减少儿童和青少年发热性疾病

Ceftriaxone alone or in Combination with Teicoplanin in the Management of Febrile Episodes in Neutropenic Children and Adolescents with Cancer on an Outpatient Base.

作者信息

Preis S, Jürgens H, Friedland C, Oudekotte-David A A, Thomas L, Göbel U

机构信息

Heinrich Heine Universität, Children's Hospital, Department of Hematology and Oncology, Düsseldorf.

出版信息

Klin Padiatr. 1993 Jul-Aug;205(4):295-9. doi: 10.1055/s-2007-1025240.

DOI:10.1055/s-2007-1025240
PMID:8377450
Abstract

STUDY OBJECTIVE

This study prospectively investigated the outpatient once daily therapy with ceftriaxone alone or if necessary in combination with teicoplanin, in the treatment of infections in children and adolescents with chemotherapy-induced neutropenia or aplastic anemia.

PATIENTS

42 patients 1-22 years of age suffering from solid tumors, hematological and oncological diseases, with clinical signs of infection, increased serum CRP (> 1 mg/dl) and/or fever above 38.5 degrees C and neutropenia (WBC count and/or ANC < 1 x 10(9)/l) were included in this outpatient based study. One important exclusion criterion was poor clinical condition with symptoms of septic shock.

METHODS

After bacterial, fungal and viral cultures had been obtained, single agent broad spectrum cephalosporin treatment was initiated with ceftriaxone applied once daily in a dose of 80 mg/kg body weight as short infusion over 30 min. Daily examinations included WBC, CRP, physical inspection and reassessment. In case of persistence or increase of fever and CRP, either outpatient management was carried on with teicoplanin added or patients were hospitalized and switched to combination antibiotic regimen.

RESULTS

There were 64 febrile episodes in 42 patients. Single agent once daily broad spectrum cephalosporin was adequate in 43/64 (67%) of infectious episodes in neutropenic patients. For persisting or increased fever or CRP elevation, 9 patients were treated with ceftriaxone and teicoplanin successfully. Thus hospitalized was avoided in 52/64 (81%) of infectious episodes.

摘要

研究目的

本研究前瞻性地调查了单独使用头孢曲松或必要时联合替考拉宁进行门诊每日一次治疗,用于治疗化疗引起的中性粒细胞减少或再生障碍性贫血的儿童和青少年感染。

患者

42例年龄在1至22岁之间,患有实体瘤、血液学和肿瘤学疾病,有感染临床体征、血清CRP升高(>1mg/dl)和/或体温高于38.5摄氏度且中性粒细胞减少(白细胞计数和/或中性粒细胞绝对值<1×10⁹/L)的患者纳入了这项基于门诊的研究。一个重要的排除标准是临床状况差且有感染性休克症状。

方法

在获得细菌、真菌和病毒培养结果后,开始使用单药广谱头孢菌素治疗,头孢曲松每日一次,剂量为80mg/kg体重,通过30分钟短时间输注给药。每日检查包括白细胞、CRP、体格检查和重新评估。如果发热和CRP持续或升高,要么继续门诊治疗并加用替考拉宁,要么将患者住院并改用联合抗生素方案。

结果

42例患者中有64次发热发作。单药每日一次广谱头孢菌素对43/64(67%)的中性粒细胞减少患者感染发作有效。对于持续发热或CRP升高的情况,9例患者使用头孢曲松和替考拉宁治疗成功。因此,52/64(81%)的感染发作避免了住院治疗。

相似文献

1
Ceftriaxone alone or in Combination with Teicoplanin in the Management of Febrile Episodes in Neutropenic Children and Adolescents with Cancer on an Outpatient Base.头孢曲松单独或与替考拉宁联合用于门诊治疗癌症中性粒细胞减少儿童和青少年发热性疾病
Klin Padiatr. 1993 Jul-Aug;205(4):295-9. doi: 10.1055/s-2007-1025240.
2
[Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriaxone administration].[采用每日一次新的头孢曲松给药方式治疗全身性血液系统疾病中的发热性中性粒细胞减少症发作]
Wien Med Wochenschr. 1998;148(21):481-7.
3
[Possibilities and limits of ambulatory supportive measures in oncology exemplified by antibiotic therapy of febrile neutropenia].[以发热性中性粒细胞减少症的抗生素治疗为例探讨肿瘤门诊支持性措施的可能性与局限性]
Wien Med Wochenschr. 1998;148(18):427-32.
4
[Antimicrobial therapy of febrile neutropenia--current developments].[发热性中性粒细胞减少症的抗菌治疗——当前进展]
Wien Med Wochenschr. 2001;151(3-4):66-72.
5
Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center.在日间治疗中心对发热幼儿的尿路感染采用每日静脉注射抗生素疗法进行治疗。
Pediatrics. 2004 Oct;114(4):e469-76. doi: 10.1542/peds.2004-0421.
6
Ceftriaxone monotherapy for the treatment of febrile neutropenia in patients with solid tumors: a prospective study of 100 episodes.头孢曲松单药治疗实体瘤患者发热性中性粒细胞减少症:100例病例的前瞻性研究
Med Sci Monit. 2004 Nov;10(11):PI119-25. Epub 2004 Oct 26.
7
Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina.门诊序贯胃肠外-口服抗生素治疗恶性疾病患儿低风险发热性中性粒细胞减少症:阿根廷一项单中心随机对照试验
Cancer. 2003 Apr 1;97(7):1775-80. doi: 10.1002/cncr.11251.
8
Empirical antibiotic therapy in febrile neutropenic patients with single-daily dose amikacin plus ceftriaxone.发热性中性粒细胞减少患者每日单次剂量阿米卡星加头孢曲松的经验性抗生素治疗。
J Med Assoc Thai. 1993 Jun;76(6):314-8.
9
[Empirical antimicrobial therapy of infection and fever episodes in children and adolescents with neutropenia caused by cytotoxic chemotherapy].[细胞毒性化疗所致中性粒细胞减少的儿童及青少年感染和发热发作的经验性抗菌治疗]
Padiatr Padol. 1989;24(1):33-42.
10
Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.比较口服阿莫西林-克拉维酸与氧氟沙星和静脉注射头孢曲松与阿米卡星作为小儿低危发热性中性粒细胞减少症门诊治疗方案的随机对照试验。
J Pediatr Hematol Oncol. 2009 Sep;31(9):635-41. doi: 10.1097/MPH.0b013e3181acd8cd.

引用本文的文献

1
Systematic review of reduced therapy regimens for children with low risk febrile neutropenia.低危发热性中性粒细胞减少症患儿简化治疗方案的系统评价
Support Care Cancer. 2016 Jun;24(6):2651-60. doi: 10.1007/s00520-016-3074-9. Epub 2016 Jan 13.
2
Outpatient therapy for febrile neutropenia: clinical and economic implications.发热性中性粒细胞减少症的门诊治疗:临床及经济影响
Pharmacoeconomics. 2003;21(6):397-413. doi: 10.2165/00019053-200321060-00004.
3
Management of febrile neutropenia in low risk cancer patients.低风险癌症患者发热性中性粒细胞减少症的管理
Thorax. 2000 Aug;55 Suppl 1(Suppl 1):S63-9. doi: 10.1136/thorax.55.suppl_1.s63.
4
Place of parenteral cephalosporins in the ambulatory setting: clinical evidence.胃肠外头孢菌素在门诊环境中的应用:临床证据
Drugs. 2000;59 Suppl 3:37-46; discussion 47-9. doi: 10.2165/00003495-200059003-00005.
5
Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.头孢曲松。对其用于治疗严重感染的药物经济学评价。
Pharmacoeconomics. 1994 Sep;6(3):249-69. doi: 10.2165/00019053-199406030-00009.
6
A survey of the use of teicoplanin in patients with haematological malignancies and solid tumours.一项关于替考拉宁在血液系统恶性肿瘤和实体瘤患者中应用情况的调查。
Infection. 1998 Nov-Dec;26(6):389-95. doi: 10.1007/BF02770842.
7
[Febrile neutropenia: practical aspects].[发热性中性粒细胞减少症:实际问题]
Med Klin (Munich). 1998 Oct 15;93(10):598-611. doi: 10.1007/BF03042675.
8
Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia.
Eur J Clin Microbiol Infect Dis. 1998 Jul;17(7):501-4. doi: 10.1007/BF01691133.
9
A risk-benefit assessment of teicoplanin in the treatment of infections.替考拉宁治疗感染的风险效益评估。
Drug Saf. 1995 Nov;13(5):317-28. doi: 10.2165/00002018-199513050-00005.